An  ||| S:0 E:3 ||| DT
analysis  ||| S:3 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
efficacy  ||| S:15 E:24 ||| JJ
data  ||| S:24 E:29 ||| NNS
from  ||| S:29 E:34 ||| IN
four  ||| S:34 E:39 ||| CD
phase  ||| S:39 E:45 ||| NN
III  ||| S:45 E:49 ||| NNP
studies  ||| S:49 E:57 ||| NNS
of  ||| S:57 E:60 ||| IN
botulinum  ||| S:60 E:70 ||| JJ
neurotoxin  ||| S:70 E:81 ||| JJ
type  ||| S:81 E:86 ||| NN
A-ABO  ||| S:86 E:92 ||| NN
for  ||| S:92 E:96 ||| IN
the  ||| S:96 E:100 ||| DT
treatment  ||| S:100 E:110 ||| NN
of  ||| S:110 E:113 ||| IN
glabellar  ||| S:113 E:123 ||| JJ
lines  ||| S:123 E:129 ||| NNS
A  ||| S:129 E:131 ||| DT
new  ||| S:131 E:135 ||| JJ
formulation  ||| S:135 E:147 ||| NN
of  ||| S:147 E:150 ||| IN
a  ||| S:150 E:152 ||| DT
botulinum  ||| S:152 E:162 ||| JJ
neurotoxin  ||| S:162 E:173 ||| JJ
type  ||| S:173 E:178 ||| NN
A  ||| S:178 E:180 ||| DT
( ||| S:180 E:181 ||| -LRB-
BoNTA-ABO ||| S:181 E:190 ||| NNP
;  ||| S:190 E:192 ||| :
Dysport  ||| S:192 E:200 ||| NNP
[ ||| S:200 E:201 ||| -LRB-
abobotulinumtoxinA ||| S:201 E:219 ||| NNP
] ||| S:219 E:220 ||| -RRB-
,  ||| S:220 E:222 ||| ,
Medicis  ||| S:222 E:230 ||| NNP
Aesthetics ||| S:230 E:240 ||| NNP
,  ||| S:240 E:242 ||| ,
Scottsdale ||| S:242 E:252 ||| NNP
,  ||| S:252 E:254 ||| ,
AZ ||| S:254 E:256 ||| NNP
)  ||| S:256 E:258 ||| -RRB-
has  ||| S:258 E:262 ||| VBZ
recently  ||| S:262 E:271 ||| RB
been  ||| S:271 E:276 ||| VBN
approved  ||| S:276 E:285 ||| VBN
in  ||| S:285 E:288 ||| IN
the  ||| S:288 E:292 ||| DT
United  ||| S:292 E:299 ||| NNP
States  ||| S:299 E:306 ||| NNPS
for  ||| S:306 E:310 ||| IN
the  ||| S:310 E:314 ||| DT
treatment  ||| S:314 E:324 ||| NN
of  ||| S:324 E:327 ||| IN
moderate  ||| S:327 E:336 ||| JJ
to  ||| S:336 E:339 ||| TO
severe  ||| S:339 E:346 ||| JJ
glabellar  ||| S:346 E:356 ||| JJ
lines ||| S:356 E:361 ||| NNS
.  ||| S:361 E:363 ||| .
We  ||| S:363 E:366 ||| PRP
describe  ||| S:366 E:375 ||| VBP
the  ||| S:375 E:379 ||| DT
results  ||| S:379 E:387 ||| NNS
of  ||| S:387 E:390 ||| IN
four  ||| S:390 E:395 ||| CD
phase  ||| S:395 E:401 ||| NN
III  ||| S:401 E:405 ||| NNP
studies  ||| S:405 E:413 ||| NNS
of  ||| S:413 E:416 ||| IN
BoNTA-ABO  ||| S:416 E:426 ||| JJ
for  ||| S:426 E:430 ||| IN
the  ||| S:430 E:434 ||| DT
treatment  ||| S:434 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
glabellar  ||| S:447 E:457 ||| JJ
lines ||| S:457 E:462 ||| NNS
.  ||| S:462 E:464 ||| .
Of  ||| S:464 E:467 ||| IN
the  ||| S:467 E:471 ||| DT
four  ||| S:471 E:476 ||| CD
studies  ||| S:476 E:484 ||| NNS
reported  ||| S:484 E:493 ||| VBD
here ||| S:493 E:497 ||| RB
,  ||| S:497 E:499 ||| ,
three  ||| S:499 E:505 ||| CD
were  ||| S:505 E:510 ||| VBD
double-blind ||| S:510 E:522 ||| JJ
,  ||| S:522 E:524 ||| ,
multicenter ||| S:524 E:535 ||| NN
,  ||| S:535 E:537 ||| ,
randomized ||| S:537 E:547 ||| NN
,  ||| S:547 E:549 ||| ,
placebo-controlled  ||| S:549 E:568 ||| JJ
studies  ||| S:568 E:576 ||| NNS
and  ||| S:576 E:580 ||| CC
one  ||| S:580 E:584 ||| PRP
was  ||| S:584 E:588 ||| VBD
an  ||| S:588 E:591 ||| DT
open-label  ||| S:591 E:602 ||| JJ
extension  ||| S:602 E:612 ||| NN
study ||| S:612 E:617 ||| NN
.  ||| S:617 E:619 ||| .
A  ||| S:619 E:621 ||| DT
second  ||| S:621 E:628 ||| JJ
phase  ||| S:628 E:634 ||| NN
III ||| S:634 E:637 ||| NNP
,  ||| S:637 E:639 ||| ,
open-label  ||| S:639 E:650 ||| JJ
extension  ||| S:650 E:660 ||| NN
study  ||| S:660 E:666 ||| NN
is  ||| S:666 E:669 ||| VBZ
ongoing ||| S:669 E:676 ||| JJ
.  ||| S:676 E:678 ||| .
Studies  ||| S:678 E:686 ||| NNS
enrolled  ||| S:686 E:695 ||| VBD
ethnically  ||| S:695 E:706 ||| RB
diverse ||| S:706 E:713 ||| JJ
,  ||| S:713 E:715 ||| ,
healthy  ||| S:715 E:723 ||| JJ
adults  ||| S:723 E:730 ||| NNS
with  ||| S:730 E:735 ||| IN
glabellar  ||| S:735 E:745 ||| JJ
lines  ||| S:745 E:751 ||| NNS
of  ||| S:751 E:754 ||| IN
at  ||| S:754 E:757 ||| IN
least  ||| S:757 E:763 ||| JJS
moderate  ||| S:763 E:772 ||| JJ
severity  ||| S:772 E:781 ||| NN
at  ||| S:781 E:784 ||| IN
maximum  ||| S:784 E:792 ||| JJ
frown ||| S:792 E:797 ||| NN
.  ||| S:797 E:799 ||| .
Patients  ||| S:799 E:808 ||| NNS
were  ||| S:808 E:813 ||| VBD
followed  ||| S:813 E:822 ||| VBN
for  ||| S:822 E:826 ||| IN
up  ||| S:826 E:829 ||| RB
to  ||| S:829 E:832 ||| TO
180  ||| S:832 E:836 ||| CD
days  ||| S:836 E:841 ||| NNS
after  ||| S:841 E:847 ||| IN
treatment ||| S:847 E:856 ||| NN
.  ||| S:856 E:858 ||| .
The  ||| S:858 E:862 ||| DT
fixed-dose ||| S:862 E:872 ||| JJ
,  ||| S:872 E:874 ||| ,
single  ||| S:874 E:881 ||| JJ
treatment  ||| S:881 E:891 ||| NN
study  ||| S:891 E:897 ||| NN
randomized  ||| S:897 E:908 ||| VBD
158  ||| S:908 E:912 ||| CD
patients  ||| S:912 E:921 ||| NNS
to  ||| S:921 E:924 ||| TO
receive  ||| S:924 E:932 ||| VB
placebo  ||| S:932 E:940 ||| NNS
or  ||| S:940 E:943 ||| CC
a  ||| S:943 E:945 ||| DT
single  ||| S:945 E:952 ||| JJ
50-unit  ||| S:952 E:960 ||| CD
BoNTA-ABO  ||| S:960 E:970 ||| JJ
dose ||| S:970 E:974 ||| NN
.  ||| S:974 E:976 ||| .
The  ||| S:976 E:980 ||| DT
fixed-dose ||| S:980 E:990 ||| JJ
,  ||| S:990 E:992 ||| ,
repeat  ||| S:992 E:999 ||| NN
treatment  ||| S:999 E:1009 ||| NN
study  ||| S:1009 E:1015 ||| NN
enrolled  ||| S:1015 E:1024 ||| VBD
311  ||| S:1024 E:1028 ||| CD
patients  ||| S:1028 E:1037 ||| NNS
to  ||| S:1037 E:1040 ||| TO
assess  ||| S:1040 E:1047 ||| VB
treatment  ||| S:1047 E:1057 ||| NN
following  ||| S:1057 E:1067 ||| VBG
repeat  ||| S:1067 E:1074 ||| JJ
BoNTA-ABO  ||| S:1074 E:1084 ||| JJ
treatment  ||| S:1084 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
50  ||| S:1097 E:1100 ||| CD
units ||| S:1100 E:1105 ||| NNS
.  ||| S:1105 E:1107 ||| .
A  ||| S:1107 E:1109 ||| DT
variable-dose  ||| S:1109 E:1123 ||| JJ
study  ||| S:1123 E:1129 ||| NN
randomized  ||| S:1129 E:1140 ||| VBD
816  ||| S:1140 E:1144 ||| CD
patients  ||| S:1144 E:1153 ||| NNS
to  ||| S:1153 E:1156 ||| TO
receive  ||| S:1156 E:1164 ||| VB
placebo  ||| S:1164 E:1172 ||| NNS
or  ||| S:1172 E:1175 ||| CC
a  ||| S:1175 E:1177 ||| DT
single  ||| S:1177 E:1184 ||| JJ
variable  ||| S:1184 E:1193 ||| JJ
dose  ||| S:1193 E:1198 ||| NN
( ||| S:1198 E:1199 ||| -LRB-
50  ||| S:1199 E:1202 ||| CD
to  ||| S:1202 E:1205 ||| TO
80  ||| S:1205 E:1208 ||| CD
units ||| S:1208 E:1213 ||| NNS
,  ||| S:1213 E:1215 ||| ,
based  ||| S:1215 E:1221 ||| VBN
on  ||| S:1221 E:1224 ||| IN
gender  ||| S:1224 E:1231 ||| NN
and  ||| S:1231 E:1235 ||| CC
muscle  ||| S:1235 E:1242 ||| NN
mass  ||| S:1242 E:1247 ||| NN
assessment ||| S:1247 E:1257 ||| NN
) ||| S:1257 E:1258 ||| -RRB-
.  ||| S:1258 E:1260 ||| .
The  ||| S:1260 E:1264 ||| DT
fourth  ||| S:1264 E:1271 ||| JJ
phase  ||| S:1271 E:1277 ||| NN
III  ||| S:1277 E:1281 ||| NNP
study  ||| S:1281 E:1287 ||| NN
was  ||| S:1287 E:1291 ||| VBD
open-label  ||| S:1291 E:1302 ||| JJ
to  ||| S:1302 E:1305 ||| TO
evaluate  ||| S:1305 E:1314 ||| VB
repeat  ||| S:1314 E:1321 ||| NN
dosing  ||| S:1321 E:1328 ||| NNS
( ||| S:1328 E:1329 ||| -LRB-
50  ||| S:1329 E:1332 ||| CD
units ||| S:1332 E:1337 ||| NNS
) ||| S:1337 E:1338 ||| -RRB-
.  ||| S:1338 E:1340 ||| .
Clinical  ||| S:1340 E:1349 ||| JJ
evaluations  ||| S:1349 E:1361 ||| NNS
were  ||| S:1361 E:1366 ||| VBD
performed  ||| S:1366 E:1376 ||| VBN
on  ||| S:1376 E:1379 ||| IN
days  ||| S:1379 E:1384 ||| NNS
14  ||| S:1384 E:1387 ||| CD
and  ||| S:1387 E:1391 ||| CC
30 ||| S:1391 E:1393 ||| CD
,  ||| S:1393 E:1395 ||| ,
and  ||| S:1395 E:1399 ||| CC
monthly  ||| S:1399 E:1407 ||| JJ
thereafter ||| S:1407 E:1417 ||| NN
.  ||| S:1417 E:1419 ||| .
Primary  ||| S:1419 E:1427 ||| JJ
efficacy  ||| S:1427 E:1436 ||| JJ
endpoints  ||| S:1436 E:1446 ||| NN
were  ||| S:1446 E:1451 ||| VBD
based  ||| S:1451 E:1457 ||| VBN
on  ||| S:1457 E:1460 ||| IN
the  ||| S:1460 E:1464 ||| DT
investigators ||| S:1464 E:1477 ||| NNS
'  ||| S:1477 E:1479 ||| ''
and  ||| S:1479 E:1483 ||| CC
patients ||| S:1483 E:1491 ||| NNS
'  ||| S:1491 E:1493 ||| POS
assessment  ||| S:1493 E:1504 ||| NN
of  ||| S:1504 E:1507 ||| IN
glabellar  ||| S:1507 E:1517 ||| JJ
line  ||| S:1517 E:1522 ||| NN
severity  ||| S:1522 E:1531 ||| NN
at  ||| S:1531 E:1534 ||| IN
day  ||| S:1534 E:1538 ||| NN
30  ||| S:1538 E:1541 ||| CD
using  ||| S:1541 E:1547 ||| VBG
wrinkle  ||| S:1547 E:1555 ||| JJ
severity  ||| S:1555 E:1564 ||| NN
rating  ||| S:1564 E:1571 ||| NN
scales ||| S:1571 E:1577 ||| NNS
.  ||| S:1577 E:1579 ||| .
Responders  ||| S:1579 E:1590 ||| NNP
were  ||| S:1590 E:1595 ||| VBD
defined  ||| S:1595 E:1603 ||| VBN
as  ||| S:1603 E:1606 ||| IN
patients  ||| S:1606 E:1615 ||| NNS
who  ||| S:1615 E:1619 ||| WP
had  ||| S:1619 E:1623 ||| VBD
a  ||| S:1623 E:1625 ||| DT
composite  ||| S:1625 E:1635 ||| JJ
2+  ||| S:1635 E:1638 ||| CD
grade  ||| S:1638 E:1644 ||| NN
improvement  ||| S:1644 E:1656 ||| NN
in  ||| S:1656 E:1659 ||| IN
wrinkle  ||| S:1659 E:1667 ||| JJ
severity ||| S:1667 E:1675 ||| NN
,  ||| S:1675 E:1677 ||| ,
meaning  ||| S:1677 E:1685 ||| VBG
that  ||| S:1685 E:1690 ||| IN
a  ||| S:1690 E:1692 ||| DT
patient  ||| S:1692 E:1700 ||| NN
had  ||| S:1700 E:1704 ||| VBD
a  ||| S:1704 E:1706 ||| DT
baseline  ||| S:1706 E:1715 ||| NN
Glabellar  ||| S:1715 E:1725 ||| NNP
Line  ||| S:1725 E:1730 ||| NNP
Severity  ||| S:1730 E:1739 ||| NNP
Scale  ||| S:1739 E:1745 ||| NNP
( ||| S:1745 E:1746 ||| -LRB-
GLSS ||| S:1746 E:1750 ||| NNP
)  ||| S:1750 E:1752 ||| -RRB-
score  ||| S:1752 E:1758 ||| NN
of  ||| S:1758 E:1761 ||| IN
2  ||| S:1761 E:1763 ||| CD
( ||| S:1763 E:1764 ||| -LRB-
moderate  ||| S:1764 E:1773 ||| JJ
glabellar  ||| S:1773 E:1783 ||| JJ
lines ||| S:1783 E:1788 ||| NNS
)  ||| S:1788 E:1790 ||| -RRB-
and  ||| S:1790 E:1794 ||| CC
a  ||| S:1794 E:1796 ||| DT
day  ||| S:1796 E:1800 ||| NN
30  ||| S:1800 E:1803 ||| CD
GLSS  ||| S:1803 E:1808 ||| JJ
score  ||| S:1808 E:1814 ||| NN
of  ||| S:1814 E:1817 ||| IN
0  ||| S:1817 E:1819 ||| CD
( ||| S:1819 E:1820 ||| -LRB-
no  ||| S:1820 E:1823 ||| DT
glabellar  ||| S:1823 E:1833 ||| JJ
lines ||| S:1833 E:1838 ||| NNS
/ ||| S:1838 E:1839 ||| JJ
none ||| S:1839 E:1843 ||| NN
) ||| S:1843 E:1844 ||| -RRB-
,  ||| S:1844 E:1846 ||| ,
or  ||| S:1846 E:1849 ||| CC
a  ||| S:1849 E:1851 ||| DT
baseline  ||| S:1851 E:1860 ||| NN
GLSS  ||| S:1860 E:1865 ||| NNP
score  ||| S:1865 E:1871 ||| NN
of  ||| S:1871 E:1874 ||| IN
3  ||| S:1874 E:1876 ||| CD
( ||| S:1876 E:1877 ||| -LRB-
severe  ||| S:1877 E:1884 ||| JJ
glabellar  ||| S:1884 E:1894 ||| JJ
lines ||| S:1894 E:1899 ||| NNS
)  ||| S:1899 E:1901 ||| -RRB-
and  ||| S:1901 E:1905 ||| CC
a  ||| S:1905 E:1907 ||| DT
day  ||| S:1907 E:1911 ||| NN
30  ||| S:1911 E:1914 ||| CD
GLSS  ||| S:1914 E:1919 ||| JJ
score  ||| S:1919 E:1925 ||| NN
of  ||| S:1925 E:1928 ||| IN
0  ||| S:1928 E:1930 ||| CD
( ||| S:1930 E:1931 ||| -LRB-
no  ||| S:1931 E:1934 ||| DT
glabellar  ||| S:1934 E:1944 ||| JJ
lines ||| S:1944 E:1949 ||| NNS
/ ||| S:1949 E:1950 ||| JJ
none ||| S:1950 E:1954 ||| NN
)  ||| S:1954 E:1956 ||| -RRB-
or  ||| S:1956 E:1959 ||| CC
1  ||| S:1959 E:1961 ||| CD
( ||| S:1961 E:1962 ||| -LRB-
mild  ||| S:1962 E:1967 ||| JJ
glabellar  ||| S:1967 E:1977 ||| JJ
lines ||| S:1977 E:1982 ||| NNS
) ||| S:1982 E:1983 ||| -RRB-
,  ||| S:1983 E:1985 ||| ,
for  ||| S:1985 E:1989 ||| IN
both  ||| S:1989 E:1994 ||| PDT
the  ||| S:1994 E:1998 ||| DT
blinded  ||| S:1998 E:2006 ||| JJ
investigator ||| S:2006 E:2018 ||| NN
's  ||| S:2018 E:2021 ||| POS
and  ||| S:2021 E:2025 ||| CC
patient ||| S:2025 E:2032 ||| NN
's  ||| S:2032 E:2035 ||| POS
assessments ||| S:2035 E:2046 ||| NNS
.  ||| S:2046 E:2048 ||| .
Patients  ||| S:2048 E:2057 ||| NNS
( ||| S:2057 E:2058 ||| -LRB-
1116  ||| S:2058 E:2063 ||| CD
total ||| S:2063 E:2068 ||| NN
;  ||| S:2068 E:2070 ||| :
720  ||| S:2070 E:2074 ||| CD
BoNTA-ABO ||| S:2074 E:2083 ||| NN
,  ||| S:2083 E:2085 ||| ,
396  ||| S:2085 E:2089 ||| CD
placebo ||| S:2089 E:2096 ||| CD
)  ||| S:2096 E:2098 ||| -RRB-
treated  ||| S:2098 E:2106 ||| VBN
with  ||| S:2106 E:2111 ||| IN
BoNTA-ABO  ||| S:2111 E:2121 ||| NNP
received  ||| S:2121 E:2130 ||| VBD
50  ||| S:2130 E:2133 ||| CD
to  ||| S:2133 E:2136 ||| TO
80  ||| S:2136 E:2139 ||| CD
units ||| S:2139 E:2144 ||| NNS
.  ||| S:2144 E:2146 ||| .
The  ||| S:2146 E:2150 ||| DT
median  ||| S:2150 E:2157 ||| JJ
duration  ||| S:2157 E:2166 ||| NN
of  ||| S:2166 E:2169 ||| IN
response  ||| S:2169 E:2178 ||| NN
was  ||| S:2178 E:2182 ||| VBD
85  ||| S:2182 E:2185 ||| CD
days  ||| S:2185 E:2190 ||| NNS
for  ||| S:2190 E:2194 ||| IN
fixed  ||| S:2194 E:2200 ||| JJ
dosing  ||| S:2200 E:2207 ||| NN
and  ||| S:2207 E:2211 ||| CC
109  ||| S:2211 E:2215 ||| CD
days  ||| S:2215 E:2220 ||| NNS
for  ||| S:2220 E:2224 ||| IN
variable  ||| S:2224 E:2233 ||| JJ
dosing ||| S:2233 E:2239 ||| NN
.  ||| S:2239 E:2241 ||| .
Similar  ||| S:2241 E:2249 ||| JJ
efficacy  ||| S:2249 E:2258 ||| NN
occurred  ||| S:2258 E:2267 ||| VBD
at  ||| S:2267 E:2270 ||| IN
doses  ||| S:2270 E:2276 ||| NNS
adjusted  ||| S:2276 E:2285 ||| VBN
for  ||| S:2285 E:2289 ||| IN
gender  ||| S:2289 E:2296 ||| NN
and  ||| S:2296 E:2300 ||| CC
muscle  ||| S:2300 E:2307 ||| NN
mass ||| S:2307 E:2311 ||| NN
,  ||| S:2311 E:2313 ||| ,
although  ||| S:2313 E:2322 ||| IN
male  ||| S:2322 E:2327 ||| JJ
patients  ||| S:2327 E:2336 ||| NNS
required  ||| S:2336 E:2345 ||| VBN
higher  ||| S:2345 E:2352 ||| JJR
doses  ||| S:2352 E:2358 ||| NNS
than  ||| S:2358 E:2363 ||| IN
female  ||| S:2363 E:2370 ||| JJ
patients  ||| S:2370 E:2379 ||| NNS
in  ||| S:2379 E:2382 ||| IN
the  ||| S:2382 E:2386 ||| DT
variable-dose  ||| S:2386 E:2400 ||| JJ
study ||| S:2400 E:2405 ||| NN
.  ||| S:2405 E:2407 ||| .
Responses  ||| S:2407 E:2417 ||| NNS
appeared  ||| S:2417 E:2426 ||| VBD
as  ||| S:2426 E:2429 ||| IN
early  ||| S:2429 E:2435 ||| JJ
as  ||| S:2435 E:2438 ||| IN
24  ||| S:2438 E:2441 ||| CD
hours ||| S:2441 E:2446 ||| NNS
,  ||| S:2446 E:2448 ||| ,
with  ||| S:2448 E:2453 ||| IN
a  ||| S:2453 E:2455 ||| DT
median  ||| S:2455 E:2462 ||| JJ
time  ||| S:2462 E:2467 ||| NN
to  ||| S:2467 E:2470 ||| TO
onset  ||| S:2470 E:2476 ||| VB
of  ||| S:2476 E:2479 ||| IN
three  ||| S:2479 E:2485 ||| CD
days ||| S:2485 E:2489 ||| NNS
.  ||| S:2489 E:2491 ||| .
The  ||| S:2491 E:2495 ||| DT
open-label  ||| S:2495 E:2506 ||| JJ
extension  ||| S:2506 E:2516 ||| NN
study  ||| S:2516 E:2522 ||| NN
evaluated  ||| S:2522 E:2532 ||| VBD
1200  ||| S:2532 E:2537 ||| CD
patients  ||| S:2537 E:2546 ||| NNS
for  ||| S:2546 E:2550 ||| IN
13  ||| S:2550 E:2553 ||| CD
months ||| S:2553 E:2559 ||| NNS
.  ||| S:2559 E:2561 ||| .
Maintenance  ||| S:2561 E:2573 ||| NN
of  ||| S:2573 E:2576 ||| IN
efficacy  ||| S:2576 E:2585 ||| NN
was  ||| S:2585 E:2589 ||| VBD
seen  ||| S:2589 E:2594 ||| VBN
after  ||| S:2594 E:2600 ||| IN
multiple  ||| S:2600 E:2609 ||| JJ
treatment  ||| S:2609 E:2619 ||| NN
cycles ||| S:2619 E:2625 ||| NNS
,  ||| S:2625 E:2627 ||| ,
indicating  ||| S:2627 E:2638 ||| VBG
that  ||| S:2638 E:2643 ||| IN
patients  ||| S:2643 E:2652 ||| NNS
did  ||| S:2652 E:2656 ||| VBD
not  ||| S:2656 E:2660 ||| RB
develop  ||| S:2660 E:2668 ||| VB
a  ||| S:2668 E:2670 ||| DT
tolerance ||| S:2670 E:2679 ||| NN
.  ||| S:2679 E:2681 ||| .
A  ||| S:2681 E:2683 ||| DT
second  ||| S:2683 E:2690 ||| JJ
open-label  ||| S:2690 E:2701 ||| JJ
study  ||| S:2701 E:2707 ||| NN
is  ||| S:2707 E:2710 ||| VBZ
ongoing  ||| S:2710 E:2718 ||| JJ
and  ||| S:2718 E:2722 ||| CC
is  ||| S:2722 E:2725 ||| VBZ
not  ||| S:2725 E:2729 ||| RB
included  ||| S:2729 E:2738 ||| VBN
in  ||| S:2738 E:2741 ||| IN
this  ||| S:2741 E:2746 ||| DT
report ||| S:2746 E:2752 ||| NN
.  ||| S:2752 E:2754 ||| .
BoNTA-ABO  ||| S:2754 E:2764 ||| NNP
significantly  ||| S:2764 E:2778 ||| RB
improved  ||| S:2778 E:2787 ||| VBN
moderate  ||| S:2787 E:2796 ||| JJ
to  ||| S:2796 E:2799 ||| TO
severe  ||| S:2799 E:2806 ||| JJ
glabellar  ||| S:2806 E:2816 ||| JJ
lines  ||| S:2816 E:2822 ||| NNS
compared  ||| S:2822 E:2831 ||| VBN
with  ||| S:2831 E:2836 ||| IN
placebo ||| S:2836 E:2843 ||| NN
,  ||| S:2843 E:2845 ||| ,
with  ||| S:2845 E:2850 ||| IN
onset  ||| S:2850 E:2856 ||| NN
of  ||| S:2856 E:2859 ||| IN
effect  ||| S:2859 E:2866 ||| NN
seen  ||| S:2866 E:2871 ||| VBN
as  ||| S:2871 E:2874 ||| IN
soon  ||| S:2874 E:2879 ||| RB
as  ||| S:2879 E:2882 ||| IN
24  ||| S:2882 E:2885 ||| CD
hours  ||| S:2885 E:2891 ||| NNS
after  ||| S:2891 E:2897 ||| IN
treatment  ||| S:2897 E:2907 ||| NN
and  ||| S:2907 E:2911 ||| CC
a  ||| S:2911 E:2913 ||| DT
median  ||| S:2913 E:2920 ||| JJ
duration  ||| S:2920 E:2929 ||| NN
of  ||| S:2929 E:2932 ||| IN
effect  ||| S:2932 E:2939 ||| NN
of  ||| S:2939 E:2942 ||| IN
85  ||| S:2942 E:2945 ||| CD
and  ||| S:2945 E:2949 ||| CC
109  ||| S:2949 E:2953 ||| CD
days  ||| S:2953 E:2958 ||| NNS
for  ||| S:2958 E:2962 ||| IN
fixed  ||| S:2962 E:2968 ||| JJ
and  ||| S:2968 E:2972 ||| CC
variable  ||| S:2972 E:2981 ||| JJ
dosing ||| S:2981 E:2987 ||| NN
,  ||| S:2987 E:2989 ||| ,
respectively ||| S:2989 E:3001 ||| RB
.  ||| S:3001 E:3003 ||| .
